Clinical Trials - September 24, 2020
Lundbeck announces positive data from the COMPLETE study
Lundbeck announces a new study that finds reduction in emotional blunting for people living with Major Depressive Disorder when treated with vortioxetine. In total, 150 patients were enrolled in the study called COMPLETE. A significant improvement in symptoms of emotional blunting as measured by Oxford Depression Questionnaire (ODQ) was observed after only one week of […]
Clinical Trials - September 14, 2020
Positive results from Lundbeck’s Vyepti study
Lundbeck has announced results from the parallel group, double-blind, randomized, placebo-controlled RELIEF study that assessed the efficacy and tolerability of Vyepti when initiated during a migraine attack in patients who are candidates for preventive therapy. The study met statistical significance on the co-primary endpoints, demonstrating that patients receiving a 100 mg Vyepti infusion during a […]
Clinical Trials - August 17, 2020
Lundbeck discontinues Schizophrenia study
Lundbeck announces the decision to discontinue the phase II proof of concept clinical study of Lu AF11167 in patients with schizophrenia, who are experiencing persistent negative symptoms. The decision to stop the trial is based on the results of a futility interim analysis, which concluded that the trial is unlikely to achieve statistical significance on […]
Careers article - June 18, 2020
Changes at Lundbeck may lead to reduction of 160 positions
As part of its Expand and Invest to Grow-strategy, Lundbeck plans to make changes to its organization in Research & Development (R&D). The initiative could lead to a reduction of around 130-160 positions globally (subject to consultation), including approximately 100 in Denmark. “The proposed changes will allow us to fully execute on our strategy in the […]
Clinical Trials - April 16, 2020
Insufficient efficacy to proceed with Lundbeck’s Tourette Syndrome study
Lundbeck has announced clinical results of a phase IIa investigational study with Lu AG06466 for the treatment of adult patients with Tourette Syndrome (TS). The randomized, double blind, placebo controlled and with individual dose titration clinical trial enrolled 48 patients at multiple sites in Europe. In this study the primary endpoint, Yale Global Tic Severity […]
Clinical Trials - April 16, 2020
Lundbeck discontinues the development of foliglurax
Lundbeck has announced that the phase IIa study (AMBLED) of its novel selective positive allosteric modulator of the glutamate 4 receptor, foliglurax, for the treatment of Parkinson’s disease did not meet the primary study endpoint. There was no statistically significant difference in change from baseline in OFF time versus placebo after a 4-week treatment period. […]
